Sie sind auf Seite 1von 1

TEAMMAUREE

Team Maureen is committed to improving the lives of


women affected by gynecological cancers. The missions of Team Maureen are to fund the most promising gynecological cancer research, raise awareness of gynecological cancer issues through educational outreach, and provide support for patients and families affected by the disease. Team Maureen was founded as a promise to a sister, daughter, wife and mother to keep her spirit alive. Maureen E. Russo passed away from relapsed cervical cancer at the age of 37 leaving her two young children behind. To honor that promise and keep Maureens competitive spirit alive, Maureens family and friends founded Team Maureen in 2007 as a Pan Mass Challenge cycling team to raise funds for cancer research at the Dana Farber Cancer Institute in Boston, MA and is now expanding into a non-profit organization. Worldwide, every two minutes a woman dies of cervical cancer. Current estimates indicate that every year 529,828 women are diagnosed with cervical cancer and 275,128 die from disease (50%). Cervical cancer ranks as the 2nd most frequent cancer in women in the World. In the US, 12,200 women are diagnosed with cervical cancer and 4,210 will die each year (1/3). Each day in the US, about 30 women learn they have cervical cancer. Human papillomavirus (HPV) is now a well-established cause of cervical cancer. HPV vaccines that prevent against HPV 16 and 18 infections are now available and have the potential to reduce the incidence of cervical cancers. Half of all women diagnosed with cervical cancer are between ages 35-55 years old, many of the women could have been exposed to cancer causing HPV types in their teens and 20s. Therefore, we are targeted this population (teens to 20s) and mothers to educate and empower. It is established that well-organized cervical screening or widespread quality cytology can reduce cervical cancer incidence and mortality. The introduction of HPV vaccination could also effectively reduce the burden of cervical cancers in the coming decades. If caught early, cervical cancer is quite treatable, whereas when it has spread it is too late. Currently, the funds we have raised for Dana-Farber Cancer Institute (DFCI) are supporting state of the art research for cervical cancer directed by Dr. Ursula Matulonis, Head of Gynecolgical (GYN) Cancers at DFCI. The project is to gain a better understanding of the molecular mutations that drive cervical cancer, and to identify targets for new therapeutic approaches to improve patient outcomes. No one has systematically examined the molecular mutations that may underlie the development of cervical cancer before this study at DFCI.

Das könnte Ihnen auch gefallen